Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.61M | -- | -298.60K | -499.40K | 6.59M |
| Total Depreciation and Amortization | 11.30K | -- | 11.50K | 11.30K | 10.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.17M | -- | -96.90K | 46.30K | -9.15M |
| Change in Net Operating Assets | -1.79M | -- | 2.30K | -389.30K | 131.30K |
| Cash from Operations | -337.70K | -- | -381.70K | -831.20K | -2.41M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -- | -3.63M | -180.70K | 7.39M |
| Cash from Investing | 0.00 | -- | -3.63M | -180.70K | 7.39M |
| Total Debt Issued | -- | -- | -- | -- | 958.60K |
| Total Debt Repaid | -24.50K | -- | -30.30K | -29.80K | -1.03M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -186.20K |
| Cash from Financing | -17.60K | -- | -22.00K | -21.60K | -182.80K |
| Foreign Exchange rate Adjustments | 1.20K | -- | 3.40K | -4.30K | -9.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -354.10K | -- | -4.03M | -1.04M | 4.78M |